| Private Placement / Financing Transactions
Commure: The company raised $200 million of venture funding from General Catalyst on June 19, 2025. The company is a developer of a cloud-based interoperable platform designed to focus on accelerating healthcare software innovation.
Juvenescence: The company raised $150 million of Series B venture funding in a deal led by M42 on June 17, 2025. Cistern Capital and other undisclosed investors also participated in the round. The company is a developer of innovative medicines designed to extend a healthy lifespan by targeting aging mechanisms.
Draig Therapeutics: The company raised GBP 107 million of Series A venture funding in a deal led by Access Industries on June 18, 2025. Sanofi Ventures, Intermediate Capital Group, Canaan Partners, SR One Capital Management, SV Health Investors and Schroders Capital also participated in the round. The company is a developer of a biotechnology platform intended to deliver effective treatments for neuropsychiatric disorders.
Tennr: The company raised $101 million of Series C venture funding in a deal led by IVP on June 18, 2025, putting the company’s pre-money valuation at $504 million. GV, Foundation Capital, Andreessen Horowitz, Lightspeed Venture Partners, Frank Slootman and ICONIQ Capital also participated in the round. The company is a developer of a healthcare workflow automation platform designed to track the lifecycle of patient referrals through the healthcare system.
Nabla: The company raised EUR 70 million of Series C venture funding in a deal led by HV Capital on June 17, 2025. Cathay Innovation, Build Collective, Highland Europe, and DST Global also participated in the round. The company is a developer of an advanced agentic AI assistant for clinicians.
Actio Biosciences: The company raised $66 million of Series B venture funding in a deal led by Regeneron Ventures and Deerfield Management on June 18, 2025. Droia Ventures, Canaan Partners and Euclidean Capital also participated in the round. The company is a developer of transformational medicines for rare diseases with high unmet need by precisely targeting underlying causes.
Corvia: The company raised $55 million of venture funding from Accelmed, General Catalyst and Third Rock Ventures on June 17, 2025. Lumira Ventures and other undisclosed investors also participated in the round. The company is a developer of a transcatheter device designed to reduce the symptoms or slow the progression of heart failure.
Sword Health: The company raised EUR 35 million of venture funding in a deal led by General Catalyst on June 17, 2025, putting the company’s pre-money valuation at $3.96 billion. Comcast Ventures, Oxy Capital, Khosla Ventures, Lince Capital, Armilar Venture Partners, Indico Capital Partners, and Shilling also participated in the round. The company is a developer of an artificial intelligence care platform focused on musculoskeletal and pelvic health care.
Glytec: The company raised $36 million of venture funding in a deal led by Hayfin Capital Management and Savitr Capital on June 17, 2025. The company is a developer of a cloud-based insulin management platform designed to improve diabetes care and insulin dosing in clinical settings.
HOPPR: The company raised $31.5 million of Series A venture funding in a deal led by Kivu Ventures and Greycroft on June 17, 2025. PSG, Morningside Capital, Fortitude Ventures, and Health2047 also participated in the round. The company is a developer of an AI medical platform for building, fine-tuning, and deploying AI foundation models and applications in the field.
Uncountable: The company raised $27 million of Series A venture funding in a deal led by Sageview Capital on June 17, 2025, putting the company’s pre-money valuation at $256 million. SE Ventures, 8VC, Teamworthy Group, MK Capital and other undisclosed investors also participated in the round. The company is a developer of an AI-powered web platform designed to support and optimize the work of scientists in the technology and manufacturing sectors.
Arima Genomics: The company raised $22 million of Series C venture funding in a deal led by Illumina Ventures on June 17, 2025. Co-Win Ventures, Berkeley Catalyst Fund, John Stuelpnagel, and Mostafa Ronaghi also participated in the round. The company is a developer of a gene-sequencing technology designed to provide access to the spatial and temporal changes in the 3D structure of the genome that alters gene regulation and cellular function
Perci: The company raised GBP 7.7 million of venture funding from Guinness Ventures, Zoas (London) and Macmillan Cancer Support on June 16, 2025, putting the company’s pre-money valuation at GBP 11.2 million. Octopus Ventures, Conduit Connect and other undisclsoed investors also participated in the round. The company is an operator of a virtual care clinic intended to connect people living with cancer and their caregivers to a team of multidisciplinary cancer experts.
GeneCentric: The company closed on $8 million of an undisclosed targeted amount of Series C venture funding in a deal led by Hatteras Venture Partners on June 18, 2025. Labcorp Venture Fund, IAG Capital Partners and Alexandria Venture Investments also participated in the round. The company is a developer of a molecular diagnostic platform designed to characterize tumor biology in a manner that facilitates optimal targeting of therapeutic compounds.
Infinity Bio: The company raised $8 million of Series A venture funding from PTX Capital, Illumina Ventures and Blackbird BioVentures on June 18, 2025. TCP Venture Capital also participated in the round. The company is an operator of a technology business that provides detailed insights into the immune system using its proprietary antibody reactome profiling platform.
AiM Medical Robotics: The company raised $6.7 million of venture funding from undisclosed investors on June 18, 2025. The company is a developer of a surgical robot designed to improve outcomes for patients undergoing neurosurgery for functional brain disorders.
Dasi Simulations: The company raised $5 million of venture funding in the form of convertible debt from K2X and other undisclosed investors on June 16, 2025. The company is a developer of AI-powered cardiac simulations to aid clinicians in planning structural heart procedures with greater precision.
Pheiron: The company raised $4.2 million of venture funding from Compound and other undisclosed investors on June 20, 2025. The company is a developer of a phenotyping platform designed to decode disease to advance new therapies.
LinusBio: The company raised $3 million of venture funding from YAC Holdings on June 16, 2025. The company is a developer of a precision exposome medicine platform designed to analyze the molecular impact of environmental exposures on health.
Layer Health: The company is in the process of raising venture funding from Intermountain Ventures on June 17, 2025. The company is an operator of an AI-powered healthcare information platform intended to help providers derive actionable insights from patient data and improve patient care.
|
